Search

Radiofrequency ablation (RFA) is a minimally invasive technology for the treatment of liver malignancies and is used as an adjuvant therapy in patients with colorectal liver metastasis (CLM). This study enrolled a total of 49 CLM patients who underwent RFA treatment. Univariate and multivariate analyses were performed using the log-rank test and Cox proportional hazard model, respectively. Univariate analysis showed that OS was closely correlated with tumor size, frequency of RFA treatment, resection of the liver lesion, and CEA levels before RFA (p p

To explore the clinical value of Lens culinaris agglutinin-reactive alpha-fetoprotein detected by microspincolum method for judgment of treatment response in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization.Twenty eight patients with HCC undergoing TACE follow-up in hospital were recruited. AFP and AFP-L3 were measured in all the patients before and after TACE, and correlations were analyzed between AFP-L3% and response to treatment.Among the twenty eight patients with HCC undergoing TACE, 8 out 11 case in AFP-L3% descent group had well treatment response, 5 out 17 case in AFP-L3% elevated group had well treatment response(Chi2 = 4. 858, P0. 05).The detection of AFP-L3 by microspincolum method is useful to judgment of treatment response in patients with HCC undergoing TACE.

To evaluate the efficacy and safety of the combination of oxaliplatin and ELF (VP16/CF/5-Fu) regimen in the treatment of patients with advanced gastric cancer.Oxaliplatin was given at a dose of 100 mg/m(2) i.v. 2 hours D1, calcium folinate (CF) 200 mg/m(2) i.v. 1/2 hour D1 approximately D3, 5-fluorouracil (5-Fu) 500 mg/m(2) i.v. 2 hours D1 approximately D3 and etoposide 100 mg/m(2) i.v. 3 hours D1 approximately D3. Cycles were repeated every 21 days. Efficacy and safety were evaluated every 2 cycles.Sixty-nine patients were enrolled into the study. All cases were pathologically confirmed as gastric cancer (adenocarcinoma in 57 cases and signet ring cell carcinoma in 12 cases). 42 patients had newly diagnosed disease, and 27 patients had received previous chemotherapy. 62 patients were analyzed for response (7 complete responses and 25 partial responses) with total response rate 51.61%. The median time to progression was 5.7 months and the median overall survival was 9.2 months. The most common hematologic toxicities were anemia (29.0%), leucopenia (51.2%) and thrombocytopenia (21.2%). No grade 4 and grade 5 hematologic toxicities were observed. The most common non-hematologic toxicities were nausea (46.5%), vomiting (41.1%), peripheral sensory neuropathy (47.1%), and grade 2 alopecia (27.3%).This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients. It is worthy to be proved as a suitable alternative regimen in this indication.

To investigate the therapeutic efficacy and adverse reactions of Aidi Injection (AI) combined with percutaneous cool-tip radiofrequency ablation (CRFA) in treatment of primary liver cancer and to explore its effect on immune function.Eighty-nine patients with primary liver cancer at middle-late stage were assigned to the control group with CRFA alone and the treatment group treated with CRFA and intravenous dripping of AI 50 mL once every day for succesive 20 days.Compared with those before treatment, the alanine aminotransferase (ALT) and albumin (ALB) levels showed no marked change, and CD4 subgroup of T lymphocyte and CD4/CD8 ratio elevated in the treatment group (P0.01), while the ALT level elevated (P0.05), ALB level decreased (P0.01), CD4 and CD4/CD8 ratio showed no change in the control group. The relapse rate was 20.0% (3/15) in patients with tumor more than 3 cm in diameter of the treatment group, which was obvious lower than that in the control group (55.0%, 11/20, P0.05).AI treatment could relieve the impairment of CRFA on hepatic function, improve immune function and reduce relapse rate in patients with primary liver cancer.

Radiofrequency (RF) can destroy local tumor tissue with less damage to the intervening tissue. The effect of RF on immune function of tumor-bearing body needs to be further investigated. This study was designed to evaluate the impact of RF on splenocyte immunity of mice bearing H22 liver cancer through detecting splenocyte proliferation, cytotoxicity, and expression pattern of cytokines T helper type 1 (Th1)/Th2.A total of 24 BALB/c mice were randomized into 4 groups: RF, surgical resection, tumor-bearing control, and normal control groups. The proliferation of splenocytes was detected by MTT assay, and the cytotoxicity of splenocytes was assayed by double-color flow cytometry (FCM). The concentrations of interferon-gamma (IFN-gamma), interleukin-2 (IL-2), IL-4, and IL-10 in splenocyte culture supernatants were detected by enzyme-linked immunoabsorbent assay (ELISA), and mRNA levels of the cytokines in splenocytes were assayed by reverse transcription-polymerase chain reaction (RT-PCR).The proliferation of splenocytes and mortality of H22 cells were significantly higher in RF group than in surgical resection group, normal control group, and tumor-bearing group (P0.05). The concentration and mRNA level of IL-2 and IFN-gamma were significantly higher in RF group than in surgical resection group, normal control group, and tumor-bearing group (P0.05); the concentration and mRNA level of IL-4 and IL-10 were significantly lower in RF group than in surgical resection group, normal control group, and tumor-bearing group (P0.05). No significant difference were found between surgical resection group and normal control group (P0.05).RF can efficiently stimulate splenocyte activation and proliferation in H22-bearing mice, and enhance splenocyte cytotoxicity to tumor cells. RF could facilitate the secretion and gene transcription of Th1 type cytokines in H22 cells.

AIM: To assess the catheterization-associated complications during intraperitoneal chemotherapy (IPCT) for advanced gastric cancer. METHODS: From 1998 to 2002, 80 patients with advanced gastric cancer received a total of 320 courses of IPCT using a large bore central venous catheter and associated complications were analyzed. RESULTS: Catheterization-associated complications occurred in 11 of the 80 patients (13.8%), including abdominal pain caused by catheter in 2 cases (0.63%), insertion failure in 2 cases (0.63%), bowel perforation in 1 case (0.31%) and abdominal pain during chemotherapy in 6 cases (1.88%). No serious complications required surgical intervention. CONCLUSION: IPCT using central venous catheters can be performed safely and simply without severe associated complications.